StemCell Therapy

CMI presents an in-depth overview of the Global Rheumatoid Arthritis Treatment Market Study, detailing the latest product/industry coverage and market forecasts and status by 2027. Market research is categorized as a key area to accelerate marketization. The current market is evolving its presence and some of the major players in the study are Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

This study focuses on the Global Rheumatoid Arthritis Treatment Market status, future forecast, growth opportunity, key market, and emerging players. The study objectives are to present the Rheumatoid Arthritis Treatment growth in Key regions. In order to provide valuable insight into each key element of the market, the highest and slowest growing market segment in the study is described. Newmarket participants are emerging and are accelerating the transition in the antistatic market. Merger and acquisition activities are expected to change the market environment for this industry.

You Keep Your Social Distance And We Provide You A Social DISCOUNT Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On All CMI Reports.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/166

The Global Rheumatoid Arthritis Treatment is segmented by:

By Product Type: Global Rheumatoid Arthritis Treatment Market, By Application.

Regional Markets: United States, Europe, China, Japan, Southeast Asia, India & Central & South America

List of Companies Mentioned: Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

1) Does Study provide Latest Impact on Market due to COVID & Slowdown?

Yes, the study has considered a chapter on Impact Analysis and this 2020 Edition of the report provides detailed analysis and its impact on growth trends and market sizing to better understand the current scenario.

2) How companies are selected or profiled in the report?

The list of some players that are profiled in the report includes Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,.. the list is sorted to come up with a sample size of at least 50 to 100 companies having greater topline value to get their segment revenue for market estimation.

** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

3) Is it possible to narrow down business segments by Application of this study?

Yes, depending upon the data availability and feasibility check by our Research Analyst, a further breakdown in business segments by end-use application in relation to type can be provided (If applicable) by Revenue Size or Volume*.

4) What is the base year of the study? What time frame is covered in the report?

Furthermore, the years considered for the study are as follows:

Historical year 2014-2019

Base year 2019

Forecast period** 2020 to 2027 [** unless otherwise stated]

Use QUARANTINEDAYS Code In Precise Requirement And Get FLAT $1,000 OFF On This Reports

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/166

** We will also include opportunities to utilize in micro markets that stakeholders can invest in, a detailed analysis of key competitors, and key services. **

Global Rheumatoid Arthritis Treatment Market What to expect from this report:

Focused Study on Niche Strategy and Market Development & penetration Scenario

Top 10 Global Rheumatoid Arthritis Treatment Companies in Global Market Share Analysis: Leaders and Laggards in 2017, 2019

Gain strategic insights on competitor information to formulate effective R&D moves

Identify emerging players and create effective counter-strategies to outpace competitive edge

Identify important and diverse product types/services offering carried by major players for market development

And many more .

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: Global Rheumatoid Arthritis Treatment MarketLandscape

PART 06: Global Rheumatoid Arthritis TreatmentMarket Sizing

PART 07: Global Rheumatoid Arthritis TreatmentMarket Segmentation

PART 08: CUSTOMER LANDSCAPE

PART 10: DECISION FRAMEWORK

PART 09: REGIONAL LANDSCAPE

PART 11: MARKET DYNAMICS: DRIVERS, TRENDS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/166

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

**Be Safe and Stay Home**

Visit link:
Rheumatoid Arthritis Treatment Market Opportunity and Business Industry By Forecast to 2026 | Coherent Market Insights.com - re:Jerusalem

A new report by XploreMR takes a deep dive into the Rheumatoid Arthritis Diagnosis Tests Market after conducting meticulous research, assessing each microscopic aspect of the market. The researches have connected the dots with minuscule details that shape into an intricate, immaculate yet elucidate study. The report presents a thoroughly scrutinized study of the Rheumatoid Arthritis Diagnosis Tests Market, leaving no stone unturned in offering market players a valuable and constructive tool that navigates them in the profitable path with the right set of objectives.

Following the methodology of Porters Five Forces analysis, the report emphasizes macro concepts such as the threat of new entries in the Rheumatoid Arthritis Diagnosis Tests Market, supplier power, threat of substitution, and buying power. Dwelling deeper into each of the factors, details about the competitive landscape, strategies of leading market players, and changes in the landscape, are also analyzed. In addition to competitive analysis, the researchers have also employed PESTEL analysis to study the impact of political, economic, social, technological, environmental, and legal factors on the keyword, thus leaving no loose ends.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.xploremr.com/connectus/sample/336

The researchers have studied the factors that are expected to drive the growth of the Rheumatoid Arthritis Diagnosis Tests by creating revenue opportunities, directly and indirectly. Similarly, the emerging trends, both long-term and short-term, present factors that are likely to impact the markets growth and project the direction the whole market is moving. Economical, technological, or any other trend that could bestow opportunities, have been studied. Moreover, the researchers have expanded the analysis beyond growth prospects and analyzed the possible restraining factors to the growth of the Rheumatoid Arthritis Diagnosis Tests Market, thus enabling market players to foresee the likely challenges and emerge successful through the forecast period 2017 2025.

In addition to the macro-economic factors that drive the global market, the market divulges micro-economic factors, diving into each individual segment such as geographical, end-use segments, and products, among others, and studies each of the segments with respect to different geographies. The geography-specific insights paint a crystal clear picture of the growth of every individual segment studied in the report, thereby enabling regional market players to leverage the trends in the region.

The report assesses key players in the Rheumatoid Arthritis Diagnosis Tests Market, studying their services, strategies, landmarks, growth plans, and recent developments. By studying multiple organizations covering small, medium, and large players the report enables emerging players to equip themselves with knowledge of competition scenarios. The most critical aspect in the competitive landscape individual growth strategy is studied extensively by dwelling into the foregoing growth trajectory of the organization. Moreover, the study paints a picture of the individual standpoints of the players in the years to come, considering the drivers and trends.

To breakdown the vast study that spreads through geographies, products, and end-use segments, among other market-specific segments, the authors present CAGR (Compound Annual Growth Rate) of each segment throughout the years of forecast. CAGR is a simplistic representation of growth that clearly projects which segment registered the highest/least growth through the forecast period 2017 2025. Moreover, each segment is analyzed on the basis of volume and volume, also projected with year-on-year growth and CAGR.

Get Your Copy at a Discounted Rate!!! Limited Time Offer!!! https://www.xploremr.com/connectus/check-discount/336

Researchers also present production and consumption analysis, key findings, important suggestions and recommendations, and other aspects, thus offering a comprehensive picture of the Rheumatoid Arthritis Diagnosis Tests Market to bolster market players in planning their strategies in the years to come.

Important Questions Answered

Highlights of TOC:

Overview: Presents a broad overview of the Rheumatoid Arthritis Diagnosis Tests market, acting as a snapshot of the elaborate study that follows.

Market Dynamics: A straight-forward discussion about key drivers, restraints, challenges, trends, and opportunities of the Rheumatoid Arthritis Diagnosis Tests market.

Product Segments: Explores the market growth of the wide variety of products offered by organizations, and how they fare with end-users.

Application Segments: This section studies the key end-use applications that contribute to the market growth and the emerging opportunities to the Rheumatoid Arthritis Diagnosis Tests market.

Geographical Segments: Each regional market with a region-specific study of each segment- is carefully assessed for understanding its current and future growth scenarios.

Company Profiles: Leading and emerging players of the Rheumatoid Arthritis Diagnosis Tests Market are thoroughly profiled in the report based on their market share, market served, products, applications, regional growth, and other factors.

Get Full Report Access athttps://www.xploremr.com/cart/336/SL

Why Do Companies Trust XMR?

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis

Contact us:

XploreMR

111 North Market Street, Suite 300,

San Jose, CA 95113, United States

Ph.No: +16692840108

E-mail id- [emailprotected]

Web: https://xploremr.com

See the original post here:
Rheumatoid Arthritis Diagnosis Tests Market Projection By Top key Players, Share, Size, Demand, Opportunities, Sale Area, Revenue Analysis Forecast To...

Global Rheumatoid Arthritis Treatment Market Research Report offers a in-depth view on market trends, forecast statistics, company profile, growth drivers and latest industry insights. The report covers all the Rheumatoid Arthritis Treatment type, applications, deployment models, research regions. A deep-dive analysis on leading Rheumatoid Arthritis Treatment industry players, their market share, production volume, gross margin analysis from 2015-2019 is provided. Challenges to the Rheumatoid Arthritis Treatment development, growth opportunities, market drivers, restraints are described in this report.

The market value, market share, production and gross margin of Rheumatoid Arthritis Treatment is covered for every type, application, and geographical regions. Also, import-export scenario, regional SWOT analysis, and market status is elaborated. Rheumatoid Arthritis Treatment Forecast covers type, application and regional forecast for market value, volume, and consumption from 2020 to 2026. Industry barriers, investment feasibility, and opportunities to the new Rheumatoid Arthritis Treatment market players are analyzed in this report.

Global Rheumatoid Arthritis Treatment market is subdivided based on type, application and research regions. Top regions studied in this report include North America, Europe, Asia-Pacific, South America, Middle East & Africa. For each region, production value and growth rate is covered from 2015 to 2019. The information on market concentration and market maturity analysis will lead to investment feasibility.

Get Free Sample(COVID-19 Impact Analysis Updated Sample):@:

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#request_sample

Major players covered in this report:

Johnson & JohnsonAmgen Inc.Sobi Inc.UCB S.A.Eli Lilly & CompanySanofi SAAbbVie Inc.Pfizer Inc.Bristol-Myers Squibb CompanyF. Hoffman-La Roche AG

Global Rheumatoid Arthritis Treatment Market Segmentation:

By Type:

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)CorticosteroidsDisease-modifying anti-rheumatic drugs (DMARDs)

By Application:

HospitalRetail PharmaciesDrugstores

Market drivers explain the emerging countries and Rheumatoid Arthritis Treatment growth. Also, the limitations, opportunities, latest industry plans, and policies are offered. Industry chain analysis explains upstream raw material suppliers, key market players, production process analysis, Rheumatoid Arthritis Treatment manufacturing cost structures, and global market share of Rheumatoid Arthritis Treatment in 2019. This in-depth study explains the cost of raw materials, labor cost, marketing channels and major downstream buyers of Rheumatoid Arthritis Treatment.

Get Up to 30% Off on purchasing this report, Ask Here for Discount @:

https://www.globalmarketers.biz/discount_inquiry/discount/146290

This study analyzes the Rheumatoid Arthritis Treatment industry market status and forecast statistics explaining the production, revenue, consumption ratio, and historic market trends. All the manufacturers, market share, company profiles, production capacity, and gross margin analysis of Rheumatoid Arthritis Treatment is presented in this report. The industry breakdown based on product type, applications, regions, and manufacturer will provide sophisticated Rheumatoid Arthritis Treatment market view. Recent Rheumatoid Arthritis Treatment developments, opportunities, challenges, and business strategies are explained. The influencing factors, product launches, mergers and acquisition of Rheumatoid Arthritis Treatment is covered in this study.

The report also explains the demand and supply side of Rheumatoid Arthritis Treatment, revenue estimates, competitive scenario, and sales data. Rheumatoid Arthritis Treatment value chain, market status, and price trends are explained in detail. Rheumatoid Arthritis Treatment industry presence across different geographies covers the regions like North America, Europe, Asia-Pacific, Middle East & Africa, and South America. Further, the countries like United States, Canada, Mexico, China, Japan, Korea, India, Australia, Indonesia, Singapore, Germany, United Kingdom, France, Italy, Spain, Russia, Brazil, Argentina, UAE, Saudi Arabia, Turkey and the rest are analyzed in this report.

Enquire For Complete Sample Report Copy Or Request For Customization:

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#inquiry_before_buying

Reasons To Buy This Report:

Rheumatoid Arthritis Treatment Report Effectively Addresses The Below Queries.

Explore Detailed Table Of Content With Table Of Figures: @

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#table_of_contents

Visit link:
Global Rheumatoid Arthritis Treatment Market Expected To Witness The Highest Growth 2027 | Johnson & Johnson, Amgen Inc., Sobi Inc., UCB SA, Eli...

Objective:To compare the efficacy and safety of brodalumab, an interleukin-17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA).

Methods:Adult patients with active PsA and inadequate response to, or intolerance to, conventional treatment were enrolled into two phase III studies (NCT02029495andNCT02024646) and randomised 1:1:1 to receive subcutaneous brodalumab 140 mg or 210 mg or placebo at weeks 0, 1 and every 2 weeks up to 24 weeks. About 30% of patients had prior use of biologics. The primary endpoint for both studies was the American College of Rheumatology 20 (ACR20) response at week 16.

Results:962 patients were randomised across the studies prior to early termination due to sponsor decision. The primary endpoint was met in both studies. Based on comparable design and eligibility criteria, data from both studies were pooled. Significantly more patients achieved ACR20 at week 16 in both brodalumab treatment groups (45.8% and 47.9% for 140 mg and 210 mg, respectively) versus placebo (20.9%) (p<0.0001). Similar results were observed at week 24. Significantly higher proportions of patients receiving brodalumab achieved ACR50/70, Psoriasis Area and Severity Index 75/90/100 and resolution of dactylitis and enthesitis versus placebo (p<0.01). Adverse event rates were similar across treatments at week 16 (54.4%, 51.6% and 54.5% for placebo, brodalumab 140 mg and 210 mg, respectively). No new safety signals were reported.

Conclusion:Brodalumab was associated with rapid and significant improvements in signs and symptoms of PsA versus placebo. Brodalumab was well tolerated, with a safety profile consistent with other interleukin-17 inhibitors.

Keywords:DMARDs (biologic); autoimmune diseases; psoriatic arthritis.

Go here to read the rest:
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials - DocWire News

Non-contact, high-resolution imaging for uveitis surveillance in juvenile idiopathic arthritis (JIA) is feasible and acceptable to patients with the disease, according to study results published in Arthritis & Rheumatology.

Disease activity in anterior uveitis is traditionally assessed using slit lamp biomicroscopy; however, this modality is semiquantitative and image interpretation is subjective. Optical coherence tomography (OCT) may represent a better metric of measuring inflammatory disease, with recent modifications to OCT allowing the imaging of the anterior chamber.

In the current study, researchers sought to assess the feasibility and accuracy of cross-sectional anterior segment OCT (AS-OCT) for the diagnosis of active uveitis in JIA.

In the cross-sectional observational study, the researchers enrolled children with and without uveitis from a specialist pediatric uveitis center in England between 2017 and 2018. The 2 groups of participants included children with JIA and a diagnosis of chronic anterior uveitis; and children without both JIA and uveitis. All children received routine clinical assessment of the anterior chamber with a slit lamp. The ordinal Standardized Uveitis Nomenclature (SUN) anterior chamber activity cell count grade was used to diagnose inflammation.

The AS-OCT scans of the anterior chamber were then acquired. Patients were asked to focus their eye that was being tested on the machine fixation beam. Image acquisition time was measured, and participants were asked to rate the acceptability of the acquisition process. The AS-OCT images were analyzed manually for the presence of anterior chamber inflammation. Examiners were blinded to the results of the initial clinical examination. Correlation between imaging-acquired cell count and clinical assessment was calculated using a multilevel linear regression model. Sensitivity, specificity, and repeatability were also reported.

A total of 26 children received AS-OCT imaging, among whom 18 (69.2%) were girls. Median age was 8 years (age range, 3-15 years). Twelve children had active anterior inflammation during their initial clinical examination. Time taken to acquire AS-OCT images from both eyes ranged from 1.5 to 22 minutes, with a median value of 8 minutes. Patients rated image acquisition acceptability as high, with a median visual analog scale score of 9.5 of a possible 10.

Intraobserver image agreement was high with regard to manual cell count (intraclass observer coefficient, 0.81; 95% CI, 0.63-0.98). There was moderate agreement on cell count between observers (kappa statistic [], 0.46; 95% CI, 0.28-0.63), and between-observer disagreement on the presence of intraocular cells in 25 of the 377 reviewed images (6.6%). Anterior segment OCT had high correlation with active inflammation as diagnosed by slit lamp examination. Sensitivity for active inflammation was 91.7% (95% CI, 61.5%-99.8%); specificity was 85.7% (95% CI, 57.2%-89.2%); and accuracy was 88.5% (95% CI, 69.9%-97.6%). In multilevel regression modeling, there was high positive correlation between clinical assessment and image-based cell count (coefficient, 3.3; 95% CI, 1.3-5.2; P =.002). No children without uveitis had a positive result on AS-OCT imaging.

These results support the feasibility and acceptability of AS-OCT imaging for the assessment of uveitis in children with JIA.

The primary study limitation was the small sample size and the fact that the study results may not be generalizable to all children with anterior chamber inflammation. While AS-OCT correlated well with slit lamp examination, further study is necessary to standardize the imaging protocol.

Imaging-based metrics for uveitis holds the promise of providing sensitive, robust, validated measurement of disease status which, alongside [standardized] datasets and patient[-centered] metrics, can also improve service provision, prognostication and precision in disease management for affected or at-risk children, the researchers concluded.

Akbarali S, Rahi JS, Dick AD, et al. Imaging based uveitis surveillance in juvenile idiopathic arthritis: feasibility, acceptability and diagnostic performance. Arthritis Rheumatol. Published online September 25, 2020. doi:10.1002/art.41530

View original post here:
Imaging-Based Uveitis Surveillance Feasible for Patients With Juvenile Idiopathic Arthritis - Rheumatology Advisor

- Researchers to share updates on long-term safety and efficacy of RINVOQ for the treatment of moderate to severe rheumatoid arthritis

- Presentations to highlight patient-reported outcomes of RINVOQ in people living with psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis

- New safety and efficacy data of RINVOQ through 64 weeks in treating ankylosing spondylitis, as well as an integrated safety analysis for psoriatic arthritis, will also be presented

NORTH CHICAGO, Ill., Oct. 28, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the presentation of new data on RINVOQ (upadacitinib) and HUMIRA (adalimumab) across multiple rheumatic diseases at the American College of Rheumatology's annual meeting (ACR Convergence 2020), to be held virtually November 5-9. A total of 38 abstracts, including seven oral presentations, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

"At AbbVie, we have a focused vision of improving the care and advancing treatment options for people living with rheumatic diseases, which is illustrated by the body of research that will be presented at this year's ACR meeting," said Marek Honczarenko M.D., Ph.D., vice president, global immunology development, AbbVie. "These data underscore the potential for RINVOQ and HUMIRA to help more people living with rheumatic diseases reach their goals."

Data evaluating the long-term safety and efficacy of RINVOQ in rheumatoid arthritis will be presented, including:

84-week data on RINVOQ as a monotherapy in patients with inadequate response to methotrexate

72-week RINVOQ monotherapy data in methotrexate-nave patients

72-week data comparing RINVOQ versus HUMIRA in patients with inadequate response to methotrexate

An integrated safety update reflecting up to three years of treatment with RINVOQ

Oral presentations will also highlight the safety and efficacy of RINVOQ in the treatment of psoriatic arthritis (through 24 weeks) and ankylosing spondylitis (through 64 weeks), while a poster presentation will provide a new integrated safety analysis from two Phase 3 trials evaluating the safety profile of RINVOQ in psoriatic arthritis.

Story continues

Further, several presentations will show patient-reported outcomes for RINVOQ in the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, including its impact on pain reduction and physical function.

Key AbbVie rheumatology abstracts in the ACR Convergence 2020 program include:

Rheumatoid Arthritis

Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis. SB Cohen, et al. Abstract Number: 0237; Poster Session: Friday, November 6, 9 11 a.m. EST

Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks. R Fleischmann, et al. Abstract Number: 0212; Poster Session: Friday, November 6, 9 11 a.m. EST

Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate: Results at 84 Weeks. JS Smolen, et al. Abstract Number: 0209; Poster Session: Friday, November 6, 9 11 a.m. EST

Incidence and Risk of Venous Thromboembolic Events Among Patients with Rheumatoid Arthritis Enrolled in the Upadacitinib Clinical Trial Program. E Choy, et al. Abstract Number: 0215; Poster Session: Friday, November 6, 9 11 a.m. EST

Upadacitinib Monotherapy in Methotrexate-nave Patients with Rheumatoid Arthritis: Results at 72 Weeks. R van Vollenhoven, et al. Abstract Number: 0207; Poster Session: Friday, November 6, 9 11 a.m. EST

Impact of Upadacitinib or Adalimumab as Initial Therapy on the Achievement of 48-week Treatment Goals in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Post Hoc Analysis of a Phase 3 Study. E Mysler, et al. Abstract Number: 0228; Poster Session: Friday, November 6, 9 11 a.m. EST

Radiographic Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib as Monotherapy or in Combination with Methotrexate: Results at 2 Years. CG Peterfy, et al. Abstract Number: 1231; Poster Session: Sunday, November 8, 9 11 a.m. EST

Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12-Week Results of a Phase 3 Study. M Bergman, et al. Abstract Number: 1728; Poster Session: Monday, November 9, 9 11 a.m. EST

Evaluation of Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis Receiving Upadacitinib: Results from a Phase 2 Open-Label Extension Study. K Winthrop, et al. Abstract Number: 1996; Oral Presentation: Monday, November 9, 10 10:50 a.m. EST

Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib. K Winthrop, et al. Abstract Number: 2002; Oral Presentation: Monday, November 9, 3 3:50 p.m. EST

Psoriatic Arthritis

Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial. MC Genovese, et al. Abstract Number: 0504; Oral Presentation: Friday, November 6, 3 3:50 p.m. EST

Impact of Upadacitinib on Reducing Pain in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials in Patients with Inadequate Response to Non-biologic or Biologic DMARDs. IB McInnes, et al. Abstract Number: 0896; Poster Session: Saturday, November 7, 9 11 a.m. EST

Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis with Inadequate Response to Non-Biologic DMARDs Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Study. V Strand, et al. Abstract Number: 1341; Poster Session: Sunday, November 8, 9 11 a.m. EST

Improvement in Patient-Reported Outcomes for Upadacitinib Versus Placebo Among Patients With Psoriatic Arthritis and an Inadequate Response to Biologic Disease-Modifying Anti-Rheumatic Drugs. V Strand, et al. Abstract Number: 1371; Poster Session: Sunday, November 8, 9 11 a.m. EST

Safety Profile of Upadacitinib in Psoriatic Arthritis: Integrated Analysis From Two Phase 3 Trials. GR Burmester, et al. Abstract Number: 1350; Poster Session: Sunday, November 8, 9 11 a.m. EST

Characterization of Remission in Patients with Psoriatic Arthritis Treated with Upadacitinib: Post-hoc Analysis from Two Phase 3 Trials. P Mease, et al. Abstract Number: 1355; Poster Session: Sunday, November 8, 9 11 a.m. EST

Efficacy and Safety of Upadacitinib versus Placebo and Adalimumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Anti-Rheumatic Drugs: A Double-Blind, Randomized Controlled Phase 3 Trial. IB McInnes, et al. Abstract Number: 2026; Oral Presentation: Monday, November 9, 11 11:50 a.m. EST

Ankylosing Spondylitis

Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs. A Deodhar, et al. Abstract Number: 0369; Poster Session: Friday, November 6, 9 11 a.m. EST

Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 1-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension. A Deodhar, et al. Abstract Number: 2023; Oral Presentation: Monday, November 9, 11 11:50 a.m. EST

A full list of all 38 AbbVie abstracts accepted for presentation at ACR Convergence 2020 can be found here.

About RINVOQ (upadacitinib)Discovered and developed by AbbVie, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.1-3 In August 2019, RINVOQ received U.S. Food and Drug Administration approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, RINVOQ was approved by the European Commission for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. The approved dose for RINVOQ in rheumatoid arthritis is 15 mg. Phase 3 trials of RINVOQ in psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, Crohn's disease, atopic dermatitis, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.4-12 Use of RINVOQ in ankylosing spondylitis and psoriatic arthritis is not approved and its safety and efficacy have not been established by regulatory authorities.

Important Safety Information about RINVOQ (upadacitinib)13

RINVOQ U.S. Use and Important Safety InformationRINVOQ is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children under 18 years of age.

What is the most important information I should know about RINVOQ?RINVOQ is a medicine that can lower the ability of your immune system to fight infections. You should not start taking RINVOQ if you have any kind of infection unless your healthcare provider (HCP) tells you it is okay.

Serious infections have happened in some people taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your HCP should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You may be at higher risk of developing shingles (herpes zoster).

Lymphoma and other cancers, including skin cancers, can happen in people taking RINVOQ.

Blood clots in the veins of the legs or lungs and arteries are possible in some people taking RINVOQ. This may be life-threatening and cause death.

Tears in the stomach or intestines and changes in certain laboratory tests can happen. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results.

What should I tell my HCP BEFORE starting RINVOQ?Tell your HCP if you:

Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection such as:

Have TB or have been in close contact with someone with TB.

Have had any type of cancer, hepatitis B or C, shingles (herpes zoster), or blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines.

Have other medical conditions including liver problems, low blood cell counts, diabetes, chronic lung disease, HIV, or a weak immune system.

Live, have lived, or have traveled to parts of the country that increase your risk of getting certain kinds of fungal infections, such as the Ohio and Mississippi River valleys and the Southwest. If you are unsure if you've been to these areas, ask your HCP.

Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines.

Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant while taking RINVOQ and for at least 4 weeks after your last dose.

Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. You should not breastfeed while taking RINVOQ and for at least 6 days after your last dose.

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

Ask your HCP or pharmacist if you are not sure if you are taking any of these medicines.

What should I tell my HCP AFTER starting RINVOQ?Tell your HCP right away if you:

Have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse.

Have any signs or symptoms of blood clots during treatment with RINVOQ, including:

Have a fever or stomach-area pain that does not go away, and a change in your bowel habits.

What are the common side effects of RINVOQ?These include: upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. These are not all the possible side effects of RINVOQ.

RINVOQ is taken once a day with or without food. Do not split, break, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it.

This is the most important information to know about RINVOQ. For more information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

Please click here for the Full Prescribing Information and Medication Guide.

About HUMIRA in the U.S.

UsesHUMIRA is a prescription medicine used:

To reduce the signs and symptoms of:

In adults, to help get moderate to severe ulcerative colitis (UC) under control (induce remission) and keep it under control (sustain remission) when certain other medicines have not worked well enough. It is not known if HUMIRA is effective in people who stopped responding to or could not tolerate anti-TNF medicines.

To treat moderate to severe chronic plaque psoriasis (Ps) in adults who are ready for systemic therapy or phototherapy, and are under the care of a doctor who will decide if other systemic therapies are less appropriate.

To treat non-infectious intermediate (middle part of the eye), posterior (back of the eye), and panuveitis (all parts of the eye) in adults and children 2 years of age and older.

Important Safety InformationHUMIRA is a TNF blocker medicine that affects the immune system and can lower the body's ability to fight infections. Serious infections have happened in people taking HUMIRA. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections. People should be tested for TB before HUMIRA use and monitored for signs and symptoms of TB during therapy, even if their TB test was negative. People at risk of TB may be treated with medicine for TB. Treatment with HUMIRA should not be started in a person with an active infection, unless approved by a doctor. HUMIRA should be stopped if a person develops a serious infection. People should tell their doctor if they live in or have been to a region where certain fungal infections are common, as these infections may happen or become more severe if people use HUMIRA. People should tell their doctor if they have had TB or hepatitis B, are prone to infections, or have symptoms such as fever, fatigue, cough, or sores.

For people taking TNF blockers, including HUMIRA, the chance of getting lymphoma or other cancers may increase. Some people have developed a rare type of cancer called hepatosplenic T-cell lymphoma. This type of cancer often results in death. If using TNF blockers, including HUMIRA, the chance of getting two types of skin cancer (basal cell and squamous cell) may increase. These types are generally not life-threatening if treated.

Other possible serious side effects with HUMIRA include hepatitis B infection in carriers of the virus; allergic reactions; nervous system problems; blood problems; certain immune reactions, including a lupus-like syndrome; liver problems; and new or worsening heart failure or psoriasis. The use of HUMIRA with anakinra or abatacept is not recommended. People using HUMIRA should not receive live vaccines. Children should be brought up to date on all vaccines before starting HUMIRA.

Common side effects of HUMIRA include injection site reactions (redness, rash, swelling, itching, or bruising), upper respiratory infections (including sinus infections), headaches, rash, and nausea.

HUMIRA is given by injection under the skin.

The benefits and risks of HUMIRA should be carefully considered before starting therapy.

Please click here for the Full Prescribing Information and Medication Guide.

About AbbVie in RheumatologyFor more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering transformative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals. For more information on AbbVie in rheumatology, visit https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/rheumatology.html.

About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.

Forward-Looking StatementsSome statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

AbbVie Data on File. ABVRRTI70713.

AbbVie Data on File. ABVRRTI70838.

AbbVie Data on File. ABVRRTI70869.

Pipeline Our Science | AbbVie. AbbVie. 2019. Available at: https://www.abbvie.com/our-science/pipeline.html. Accessed on August 17, 2020.

Burmester G.R., et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018 Jun 23;391(10139):2503-2512. doi: 10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy. ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT02365649. Accessed on August 17, 2020

A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT02819635. Accessed on August 17, 2020.

A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis (SELECT Axis 1). ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/study/NCT03178487. Accessed on August 17, 2020.

A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA). ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT03725202. Accessed on August 17, 2020.

A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis. ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/record/NCT03607422. Accessed on August 17, 2020.

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (SELECT - PsA 1). ClinicalTrials.gov. 2020. Available at: https://clinicaltrials.gov/ct2/show/NCT03104400. Accessed on August 17, 2020.

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-TAK). ClinicalTrials.gov. 2020. Available at https://clinicaltrials.gov/ct2/show/record/NCT04161898. Accessed on October 13, 2020.

RINVOQ (upadacitinib) [Package Insert]. North Chicago, Ill.: AbbVie Inc.

View original content:http://www.prnewswire.com/news-releases/abbvie-highlights-innovative-research-for-people-with-rheumatic-diseases-with-new-data-at-acr-convergence-2020-301161316.html

SOURCE AbbVie

See the original post:
AbbVie Highlights Innovative Research for People with Rheumatic Diseases with New Data at ACR Convergence 2020 - Yahoo Finance

Fact.MR has recently published a report, titled [Global Rheumatoid Arthritis Stem Cell Therapy Market 2020 by Key Countries, Companies, Type and Application]. The research report provides an in-depth explanation of the various factors that are likely to drive the market. It discusses the future of the market by studying the historical details. Analysts have studied the ever-changing market dynamics to evaluate their impact on the overall market. In addition, the report also discusses the segments present in the market. Primary and secondary research methodologies have been used to provide the readers with an accurate and precise understanding of the overall The Rheumatoid Arthritis Stem Cell Therapy market. Analysts have also given readers an unbiased opinion about the direction companies will take during the forecast period.

The research report also includes the global market figures that provide historical data as well as estimated figures. It gives a clear picture of the growth rate of the market during the forecast period. The report aims to give the readers quantifiable data that is collected from verified data. The report attempts to answer all the difficult questions such as market sizes and company strategies.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Competitive landscape

Global Rheumatoid Arthritis Stem Cell Therapy Market: Drivers and Restraints

The report explains the drivers shaping the future of the Rheumatoid Arthritis Stem Cell Therapy market. It evaluates the various forces that are expected to create a positive influence on the overall market. Analysts have studied the investments in research and development of products and technologies that are expected to give the players a definite boost. Furthermore, researchers have also included an analysis of the changing consumer behavior that is projected to impact the supply and demand cycles present in the global The Rheumatoid Arthritis Stem Cell Therapy market. Evolving per capita earnings, improving economic statuses, and emerging trends have all been studied in this research report.

The research report also explains the potential restraints present in the global The Rheumatoid Arthritis Stem Cell Therapy market. It evaluates the aspects that are likely to hamper the market growth in the near future. In addition to this assessment, it also provides a list of opportunities that could prove lucrative to the overall market. Analysts provide solutions for turning threats and restraints into successful opportunities in the coming years.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Global Rheumatoid Arthritis Stem Cell Therapy Market: Regional Segmentation

In the successive chapters, analysts have studied the regional segments present in the global The Rheumatoid Arthritis Stem Cell Therapy market. This gives the readers a narrowed-view of the global market enabling a closer look at the elements that could define its progress. It highlights myriad regional aspects such as the impact of culture, environment, and government policies that influence the regional markets.

Global Rheumatoid Arthritis Stem Cell Therapy Market: Competitive Landscape

The last chapter of the global The Rheumatoid Arthritis Stem Cell Therapy market research report focuses solely on the competitive landscape. It studies the key players present in the market. In addition to a brief overview of the company, analysts shed light on their valuation and evolution. It also mentions the list of important products and the ones in the pipeline. The competitive landscape is analyzed by understanding the strategies of the companies and the initiatives they have taken in recent years to overcome the intensive competition.

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Read the rest here:
Innovations in the Rheumatoid Arthritis Stem Cell Therapy Field Likely to Aid the Growth of the Rheumatoid Arthritis Stem Cell Therapy Market 2018 to...

Joint pain resulting in arthritis is a common health problem and if you are suffering from arthritis, there are certain foods you need to avoid to prevent from worsening your health conditions. Find out more.

Arthritis is a common health issue that occurs in many adults and younger people. It involves inflammation in your joints that leads to weakening the bones and damaging them. Some people believe that changes in diet are related to increased symptoms in arthritis. This change might be excess of fat and sugar or avoiding foods that are high in purines.

Let us have a look at five types of food that should be avoided if you are suffering from arthritis:

Inflammatory fats

Since inflammatory fats cause inflammation in the body, they are to be avoided by people with arthritis. Foods which include Omega 6 fatty acids like oil, corn, sunflower and vegetable oil. Saturated fat like meat, butter, cheese and trans fat. Trans fat is bad for health anyway as it increases the level of bad cholesterol in the body.

Sugar

People who have processed sugar regularly in their tea or coffee are highly prone to being at risk for having heart strokes. It leads to obesity, inflammation and other chronic diseases. Limit your intake of carbonated drinks, sugar in beverages, cereal bowls and other food items.

Tomatoes, eggplant, potatoes, bell peppers

Removing these food items from your diet or as part of key ingredients in your dishes might help. This improves in reducing the chances of developing any symptoms related to arthritis.

Purines

These are foods that are high in purines, which are substances in foods that the body converts to uric acid. The uric acid can accumulate in blood causing a gout attack. These types of foods include red meat, beer, ham and seafood.

Also Read:What are Shingles and is stress the real cause? Heres all you need to know

x Your comment has been submitted to the moderation queue

Read more from the original source:
THESE are the 5 foods people who suffer from arthritis must avoid - PINKVILLA

The report referring to the Systemic Idiopathic Juvenile Arthritis Treatment market is one of the most widespread and with key impactful additions designed for the buyers. Market Growth Insight has delivered detailed analysis and research on the major aspects of the market including the drivers, restraints, opportunities, challenges, and threats of the market. Complete study on these factors helps the buyers of the report to plan crucial decisions for the upcoming years and gain top rankings among competitors. The Systemic Idiopathic Juvenile Arthritis Treatment market research report is segmented in different key verticals, such as product, application, end user, and geography that are all described with useful information to assist the industry players with their future planning. Also, the report is decorated with the current happenings like ongoing trends, opportunities for the Systemic Idiopathic Juvenile Arthritis Treatment market players, recent news, key developments, and recently adopted strategies. The report also delivers key information like company profiles, import and export, sales, revenues, and more.

North America has a significant international presencein the global Systemic Idiopathic Juvenile Arthritis Treatment market in 2020 accompanied by the Middle East/Africa, Europe, and the Asia Pacific, respectively.

Avail your SAMPLE of the Systemic Idiopathic Juvenile Arthritis Treatment Market Report, here @https://www.marketgrowthinsight.com/sample/16866

Top Leading players operating in the market: Alteogen Inc., Bristol-Myers Squibb Company, Epirus Biopharmaceuticals, Inc., Johnson & Johnson, Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., Novartis AG, Oncobiologics, Inc.

Segmentation by Product:

Segmentation by Application:

Growth Dynamics and Geographical Landscape:

The Systemic Idiopathic Juvenile Arthritis Treatment market research report delivers the existing growth changes witness in the industry by the researchers and experts. The report offers thorough analysis on the recent adopted growth strategies by the leading players and offers comprehensive impactful information that helps the new entrants and other existing players to plan their strategies accordingly. The report also provides complete analysis with deep research on the various key geographies that have marked the growth of the Systemic Idiopathic Juvenile Arthritis Treatment market with optimal sales, product demand in the region, distributors, marketing strategies, product pricing, and more. The report covers key insights on the current happenings that will assist the business, companies, investors, and others to understand the scenario of the Systemic Idiopathic Juvenile Arthritis Treatment market, plan activities, and gain prominent positions in the near future.

Report on Systemic Idiopathic Juvenile Arthritis Treatment market will help with the following questions:

1. Which are the leading industry players in the Systemic Idiopathic Juvenile Arthritis Treatment market?2. What is the expected size of the Systemic Idiopathic Juvenile Arthritis Treatment market in the forecast period?3. Which category is anticipated to lead the global Systemic Idiopathic Juvenile Arthritis Treatment market in the near future?4. What are the current trends and key developments that are expected to impact the market significantly by the end of 2025?5. What is the landscape of the competitive scenario of the global Systemic Idiopathic Juvenile Arthritis Treatment market?6. What are the most commonly adopted growth strategies adopted by the dominating players in the Systemic Idiopathic Juvenile Arthritis Treatment market?

Grab Your Report at an Impressive Discount! Please click Here @ https://www.marketgrowthinsight.com/discount/16866

Table of Contents:

Market Overview: This is the first section of the report that includes an overview of the scope of products offered in the global Systemic Idiopathic Juvenile Arthritis Treatment market, segments by product and application, and market size.

Market Competition by Player: Here, the report shows how the competition in the global Systemic Idiopathic Juvenile Arthritis Treatment market is growing or decreasing based on deep analysis of market concentrate rate, competitive situations and trends, expansions, merger and acquisition deals, and other subjects. It also shows how different companies are progressing in the global Systemic Idiopathic Juvenile Arthritis Treatment market in terms of revenue, production, sales, and market share.

Company Profiles and Sales Data: This part of the report is very important as it gives statistical as well as other types of analysis of leading manufacturers in the global Systemic Idiopathic Juvenile Arthritis Treatment market. It assesses each and every player studied in the report on the basis of main business, gross margin, revenue, sales, price, competitors, manufacturing base, product specification, product application, and product category.

Market Status and Outlook by Region: The report studies the status and outlook of different regional markets such as Europe, North America, the MEA, Asia Pacific, and South America. All of the regional markets researched about in the report are examined based on price, gross margin, revenue, production, and sales. Here, the size and CAGR of the regional markets are also provided.

Market Forecast: It starts with revenue forecast and then continues with sales, sales growth rate, and revenue growth rate forecasts of the global Systemic Idiopathic Juvenile Arthritis Treatment market. The forecasts are also provided taking into consideration product, application, and regional segments of the global Systemic Idiopathic Juvenile Arthritis Treatment market.

Marketing Strategy Analysis, Distributors: Here, the research study digs deep into behaviour and other factors of downstream customers, distributors, development trends of marketing channels, and marketing channels such as indirect marketing and direct marketing.

Research Findings and Conclusion: This section is solely dedicated to the conclusion and findings of the research study on the global Systemic Idiopathic Juvenile Arthritis Treatment market.

Make an Enquiry for purchasing this Report @ https://www.marketgrowthinsight.com/inquiry/16866

About Market Growth Insight

We are striving to provide the best customer friendly services and appropriate business information to accomplish your ideas. The skilled and experienced professionals at Market Growth Insight are our strength and the position we have earned in the industry. This is what makes us to offer our clients to excel and enable competitive prices while retaining the best services. We are incorporated with a vision to provide the complete solution required for successful business execution. Our only motto is to resolve customer fulfillment completely. We provide the quality and customized research reports from the best publishers in the world.

Contact Us:

Direct Line:+1 3477675477 (US)Email:[emailprotected]Web:https://www.marketgrowthinsight.com

Read more:
Get In Depth Analysis Of How Covid-19 Is Impacting The Systemic Idiopathic Juvenile Arthritis Treatment Market - The Think Curiouser

The Rheumatoid Arthritis Diagnosis Tests market report is an ultimate solution for businesses if they want to stay ahead of the competition in todays fast moving business environment.

What is more, business can also have details about historic data, present market trends, future product environment, marketing strategies, technological innovation, upcoming technologies, emerging trends or opportunities, and the technical progress in the related industry in this Rheumatoid Arthritis Diagnosis Tests market analysis report.

This Rheumatoid Arthritis Diagnosis Tests market report is mainly delivered to the users in the form of PDF or spreadsheet. However, PPT format can also be offered if the client has specified such requirement.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2814797&source=atm

Rheumatoid Arthritis Diagnosis Tests Market Characterization-:

The overall Rheumatoid Arthritis Diagnosis Tests market is characterized on the basis of different analysis-:

Rheumatoid Arthritis Diagnosis Tests market is expected to grow at a rate of X.XX% in the forecast period 2020 to 2027.

Global Rheumatoid Arthritis Diagnosis Tests Market Scope and Market Size

Global Rheumatoid Arthritis Diagnosis Tests market is segmented on the basis of type and application. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

On the basis of type, Rheumatoid Arthritis Diagnosis Tests market is segmented into platform as a service and application program interface.

The application segment of the Rheumatoid Arthritis Diagnosis Tests market is divided into personal use, large enterprise, small medium enterprise (SMEs), and other

Rheumatoid Arthritis Diagnosis Tests Market Country Level Analysis

Global Rheumatoid Arthritis Diagnosis Tests market is analysed and market size, volume information is provided by type and application as referenced above.

Key Rheumatoid Arthritis Diagnosis Tests market players Analysis-:

The study given in this section offers details of key market players. It likewise clarifies the marketing strategies adopted by these players as well as portrays their shareholdings in the Rheumatoid Arthritis Diagnosis Tests market.

segment by Type, the product can be split intoSerology TestsMonitoring RA Treatment Efficiency Tests

Market segment by Application, split intoDiagnostic LaboratoriesAmbulatory Surgical CentersHospitals

Based on regional and country-level analysis, the Rheumatoid Arthritis Diagnosis Tests market has been segmented as follows:North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of Asia-PacificLatin AmericaMexicoBrazilMiddle East & AfricaTurkeySaudi ArabiaUAERest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Rheumatoid Arthritis Diagnosis Tests market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this studyAbbottBeckman CoulterEuro DiagnosticaRocheQiagenSiemens HealthcareThermo Fisher ScientificBio Rad LaboratoriesAviva Systems Biology

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2814797&source=atm

Regional Segments Analysis:

The Middle East and Africa (GCC Countries and Egypt.)

North America (the United States, Mexico, and Canada.)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia.)

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2814797&licType=S&source=atm

Set of Chapter covered in this report-:

Part 01: Rheumatoid Arthritis Diagnosis Tests Market Overview

Part 02: Manufacturers Profiles

Part 03: Global Rheumatoid Arthritis Diagnosis Tests Market Competition, by Players

Part 04: Global Rheumatoid Arthritis Diagnosis Tests Market Size by Regions

Part 05: North America Rheumatoid Arthritis Diagnosis Tests Revenue by Countries

Part 06: Europe Rheumatoid Arthritis Diagnosis Tests Revenue by Countries

Part 07: Asia-Pacific Rheumatoid Arthritis Diagnosis Tests Revenue by Countries

Part 08: South America Rheumatoid Arthritis Diagnosis Tests Revenue by Countries

Part 09: Middle East and Africa Revenue Rheumatoid Arthritis Diagnosis Tests by Countries

.so on

For More Information Kindly Contact:

ResearchMoz

Mr. Rohit Bhisey,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

View post:
Global Rheumatoid Arthritis Diagnosis Tests Market : Current Trends and Future Estimations to Elucidate Imminent Investment Pockets - The Think...

The global canine arthritis treatment market is expected to rise with an impressive CAGR and generate the highest revenue by 2026.Fortune Business Insights in its latest report published this information. The report is titled Canine Arthritis Treatment Market Size, Share and Global Trend By Product (Surgical Procedures, Medications, Nutritional Therapy, Others), and Geography Forecast till 2026. The report discusses research objectives, research scope, methodology, timeline and challenges during the entire forecast period. It also offers an exclusive insight into various details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies.

For more information, Get sample pdf @https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/canine-arthritis-treatment-market-100675

The report provides a 360-degree overview of the market, listing various factors restricting, propelling, and obstructing the market in the forecast duration. The report also provides additional information such as interesting insights, key industry developments, detailed segmentation of the market, list of prominent players operating in the market, and other canine arthritis treatment market trends. The report is available for sale on the company website.

some of the key players in the global Canine Arthritis Treatmentmarket:

North America to dominate the global market

Geographically, the global canine arthritis treatment market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. North America is presently leading the global canine arthritis treatment market. The region is predicted to dominate the global canine arthritis treatment market during the forecast period, owing to the rising prevalence of canine arthritis and growing ownership of pet dogs. According to the American Pet Products Association, an estimated 94.2 million cats and 89.7 million dogs are owned by households in the U.S. during 2017. The Asia-pacific followed by Middle East & Africa are predicted to grow significantly during the forecast period due to increasing ownership of dogs and increasing awareness of canine arthritis in the region. In addition, developing veterinary healthcare infrastructure in emerging countries such as China and India are anticipated to fuel demand for canine arthritis treatment and hence fostering the growth of global canine arthritis treatment market during the forecast period

View press release for more information @https://www.fortunebusinessinsights.com/industry-reports/canine-arthritis-treatment-market-100675

Regional Analysis for Canine Arthritis Treatment Market:

Major Table of Contents for Canine Arthritis Treatment Market:

Other Exclusive Reports:

Drug Eluting Stent Market

Urinalysis Market

Disposable Respirators Market

Patient Engagement Solutions Market

SUBSTANCE ABUSE TREATMENT Market

Syphilis Rapid Test Kits Market

Muscarinic Acetylcholine Receptor Market

About Us:Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

Contact:Name: Ashwin AroraEmail:[emailprotected]Phone: US +1 424 253 0390 / UK +44 2071 939123 / APAC: +91 744 740 1245

View original post here:
Canine Arthritis Treatment Market 2020 | Global Trends, Covid-19 Impact, Share, Insights, Growth, and Outlook upto 2026 - Aerospace Journal

Until now, immunotherapy has relied on revving up just one arm of the immune system against tumors. But scientists reported Thursday that in animal experiments, they trained a different arm to beat back cancer, pointing to a new potential treatment pathway.

Existing cancer immunotherapies exploit the adaptive immune system. That is also what vaccines, like those being developed against Covid-19, target, by introducing a piece of a viral or bacterial invader to the adaptive system so it learns to fight that specific microbe. In contrast, the innate immune system the one we are born with recognizes pathogens and patterns of damage in a more general way. It was once thought to be fixed, but over the last several years, the innate system has revealed itself to be teachable, too.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

Read more here:
Training the innate immune system to thwart cancer could aid therapy - STAT

SEATTLE It's difficult to anticipate who will contract the coronavirus and how well their immune system will withstand the attack. We're taking external precautions by wearing masks, social distancing, and staying home but what else can we do lower our risk? We had the opportunity to talk with Dr. Samira Ummat from Longevity Medical Clinic about steps we can take to protect ourselves and strengthen our immune systems. She said it's possible for the body to improve immune response but it's not a one-size-fits all situation. It often involves a combination of increasing activity level, reducing stress, optimizing hormones, improving the quality and quantity of sleep, and optimizing micro and macronutrients.

To diagnose the best approach for each patient Longevity Medical Clinic starts with a free Health Analysis Appointment, "We offer two free tests, first a blood test, and secondly a special InBody test to help determine basic risk factors, such as dementia, cardiovascular disease, diabetes, brain shrinkage and more. Again, if you dont measure, you dont know."

Read the original here:
How to protect your health by strengthening your immune system - KING5.com

Some survivors of Covid-19 carry worrying signs that their immune system has turned on the body, reminiscent of potentially debilitating diseases like lupus and rheumatoid arthritis, a new study has found.

At some point, the bodys defense system in these patients shifted into attacking itself, rather than the virus, the study suggests. The patients are producing molecules called autoantibodies that target genetic material from human cells, instead of from the virus.

This misguided immune response may exacerbate severe Covid-19. It may also explain why so-called long haulers have lingering problems months after their initial illness has resolved and the virus is gone from their bodies.

The findings carry important implications for treatment: Using existing tests that can detect autoantibodies, doctors could identify patients who might benefit from treatments used for lupus and rheumatoid arthritis. There is no cure for these diseases, but some treatments decrease the frequency and severity of flare-ups.

Its possible that you could hit the appropriate patients harder with some of these more aggressive drugs and expect better outcomes, said Matthew Woodruff, an immunologist at Emory University in Atlanta and lead author of the work.

The results were reported Friday on the preprint server MedRxiv, and have not yet been published in a scientific journal. But other experts said the researchers who carried out the study are known for their careful, meticulous work, and that the findings are not unexpected because other viral illnesses also trigger autoantibodies.

Im not surprised, but its interesting to see that its really happening, said Akiko Iwasaki, an immunologist at Yale University. Its possible that even moderate to mild disease may induce this kind of antibody response.

For months it has been clear that the coronavirus can cause the immune system to run amok in some people, ultimately wreaking more damage to the body than the virus itself. (Dexamethasone, the steroid President Trump took after his Covid diagnosis, has proved effective in some people with severe Covid to tamp down this over-exuberant immune response.)

Viral infections cause infected human cells to die. Sometimes the cells die a quiet death but sometimes, and especially in the throes of severe infection, they can blow up, strewing their innards. When that happens, DNA, normally cloistered in coiled bundles inside the nucleus, is suddenly scattered and visible.

In the typical response to a virus, cells known as B immune cells make antibodies that recognize pieces of viral RNA from the virus and lock onto them.

But in conditions like lupus, some B cells never learn to do this and instead produce autoantibodies that glom onto DNA debris from dead human cells, mistaking them for intruders. Something similar may be happening in patients with Covid-19, the research suggests.

Anytime you have that combination of inflammation and cell death, there is the potential for autoimmune disease and autoantibodies, more importantly, to emerge, said Marion Pepper, an immunologist at the University of Washington in Seattle.

Dr. Woodruff and his colleagues reported earlier this month that some people with severe Covid-19 also have such unrefined B immune cells. The finding prompted them to explore whether those B cells make autoantibodies.

In the new study, the researchers looked at 52 patients within the Emory health care system in Atlanta who were classified as having either severe or critical Covid-19, but who had no history of autoimmune disorders.

They found autoantibodies that recognize DNA in nearly half of the patients. They also found antibodies against a protein called rheumatoid factor and others that help with blood clotting. Among the top half of the most seriously ill patients, more than 70 percent had autoantibodies against one of the targets tested, Dr. Woodruff said.

Its not just that these patients have an autoimmune-like immune response, he said. Its that those immune responses are coupled with actual true testable clinical auto-reactivities.

Some of the autoantibodies the researchers identified are associated with blood flow problems, noted Ann Marshak-Rothstein, an immunologist and lupus expert at the University of Massachusetts, Worcester.

Its very possible that some of the coagulation issues that you see in Covid-19 patients are being driven by these kinds of immune complexes, she said.

If the autoantibodies do turn out to be long-lasting, she said, they may result in persistent, even lifelong, problems for Covid-19 survivors.

You never really cure lupus they have flares, and they get better and they have flares again, she said. And that may have something to do with autoantibody memory.

Dr. Marshak-Rothstein, Dr. Iwasaki and dozens of other teams are closely studying the immune response to the coronavirus. Given the ease of testing for autoantibodies, it may soon become clear whether the antibodies were identified only because the researchers went looking for them, or whether they represent a more permanent alteration of the immune system.

Its not clear to me what it all means at this point, Dr. Pepper said. Its going to take a little bit of time to understand if this is something thats going to lead to downstream pathology.

Read the rest here:
Some Covid Survivors Have Antibodies That Attack the Body, not Virus - The New York Times

The portion of people in Britain with detectable antibodies to the coronavirus fell by roughly 27 percent over a period of three months this summer, researchers reported Monday, prompting fears that immunity to the virus is short-lived.

But several experts said these worries were overblown. It is normal for levels of antibodies to drop after the body clears an infection, but immune cells carry a memory of the virus and can churn out fresh antibodies when needed.

Some of these headlines are silly, said Scott Hensley, an immunologist at the University of Pennsylvania.

Declining antibody levels after the acute infection has resolved is the sign of a normal healthy immune response, Dr. Hensley said. It doesnt mean that those people no longer have antibodies. It doesnt mean that they dont have protection.

The research also raised some fears about the ability of vaccines to help populations reach herd immunity, the point at which enough people would be immune to the coronavirus to thwart its spread.

Its too early to know how long immunity to the new coronavirus lasts, and whether people can be reinfected many months to a year after a first bout with the virus. Still, experts said worries about vaccines, too, are unwarranted.

The vaccine doesnt have to mimic or mirror the natural infection, said Shane Crotty, a virologist at the La Jolla Institute for Immunology. Certainly I wouldnt be alarmist about these data.

The new results indicate the prevalence of coronavirus antibodies in the broader population but not in specific individuals. Several studies looking at antibody levels in individuals have shown that after some initial decline, the levels hold steady for at least four to seven months.

The British report is based on three rounds of antibody blood tests carried out in 350,000 randomly selected people from June 20 to Sept. 28. The participants tested themselves at home for antibodies using finger-prick assays that deliver a yes-or-no result, much like a pregnancy test.

Over the three-month period, the proportion of people with detectable antibodies in their blood dropped to 4.8 percent from 6 percent, the researchers reported. The smallest decline was among people ages 18 to 24 and the biggest in those over age 75.

Looking at the data a different way, about 73 percent of people who had antibodies early on still produced a positive result months later, noted Dr. Antonio Bertoletti, a virologist at Duke NUS Medical School in Singapore. Thats not such a dramatic decline.

Antibodies also represent only one arm of the immune response, albeit the one that can most easily be measured. There are at least three other branches of the immune system that can fend off illness, so antibody levels dont present the full picture.

Its not the whole immune response, said Dr. Paul Elliott, an epidemiologist at Imperial College London who heads the project.

When the body encounters a pathogen, it rapidly produces antibodies that recognize the invader. Once the acute infection resolves, the levels decline as they must for purely practical reasons.

Our lymphatic system, where immune cells are, only has a finite amount of space, Dr. Hensley said.

Depending on the test used, the small amount of antibodies still circulating in the blood may not be enough for a positive signal. The test used in the study has a sensitivity of 84.4 percent, well below that of lab-based tests that hover around 99 percent. That means it may miss anyone who has low antibody levels.

For example, people with mild to no symptoms may have produced fewer antibodies than those with severe illness. Most of the people with positive results were ill in March or April, at the peak of the outbreak in Britain, but about 30 percent did not recall having any Covid-19 symptoms. Even a small decrease in the amount of antibodies may drop their levels below the limit of detection.

Confused by the terms about coronavirus testing? Let us help:

Were saying the antibody response has declined below the threshold of detection, Dr. Elliott said. This is not a surprise to anyone who works in the field.

Data from monkeys suggests that even low levels of antibodies can prevent serious illness from the virus, if not a re-infection. Even if circulating antibody levels are undetectable, the body retains the memory of the pathogen. If it crosses paths with the virus again, balloon-like cells that live in the bone marrow can mass-produce antibodies within hours.

A very small number of people may not make any antibodies. But even those people may have immune cells called T cells that can identify and destroy the virus. The vast majority of people infected with the coronavirus develop lasting cellular responses, according to several recent studies.

T cells are unlikely to prevent infection, but they may at least prevent serious illness by blunting the attack, Dr. Crotty said. Given all that, he said, interpreting low antibody levels to mean that immunity disappears, or that coronavirus vaccines will not be effective is wrong.

For example, the human papillomavirus elicits a terrible immune response and lousy antibodies, he said. But the vaccine with a single immunization elicits fantastic antibodies that are 99 percent protective in people for 10-plus years, just a complete night-and-day difference.

Vaccines can also be designed to provoke much stronger responses than the natural infection, he added.

Though criticizing many of the interpretations of it, experts said the new studys results are an interesting glimpse into the prevalence of antibodies at a population level.

The same research team is also testing hundreds of thousands of people for presence of the virus. Together, Dr. Elliott said, the studies offer a really powerful tool for policymakers to gauge the size of a countrys epidemic.

Link:
Why You Shouldnt Worry About Studies Showing Waning Coronavirus Antibodies - The New York Times

Winteralways gets us thinking about doing our best to ward off bugs and colds and this year, immunity is on our minds more than ever.

The immune system is a lot more complex than we often give it credit for a fascinating network of cells, organs, proteins and tissues with a very important job: to protect the body from outside invaders, like bacteria, viruses and parasites.

Its working away in the background continuously and many different factors play a role in how it functions, including number of things in our day-to-day lifestyles.

While avoiding bugs (with good hand-washing, etc) is one of the single most important things for keeping winter bugs at bay, our own habits and lives can also play a part in supporting our immune system as well as possibly doing it no favours at all.

Heres five ways you might be sabotaging your immune system

1. Smoking:

Its common knowledge smoking has a harmful effect on many different areas of the body, and the delicate balance of the immune system is no different.

Smoking increases inflammation in the body, which can eventually lead to chronic inflammatory disorders, such as heart disease, asthma and arthritis explains Emily Rollason, senior nutritionist at Holland & Barrett (hollandandbarrett.com).

Smoking can also reduce absorption and usage of certain nutrients that are beneficial for immune system support, such as Vitamins B12, C and D; in fact, its well known that smokers have higher requirements for these nutrients.

Rollason says quitting smoking is not only beneficial for your heart and lungs, but also vital to ensure your body can make a good recovery when it encounters a winter bug. Speak to a healthcare professional if you are looking to quit, as they can talk to you about ways they can support you through the process.

Quitting smoking can help your body to make a better recovery after colds and flus

2. Not getting enough sleep:

Missing out on good quality sleep is something that affects us in more ways than we realise. Getting the right amount of sleep is extremely important, particularly when it comes to the adaptive immune response, says Rollason.

Rollason explains that the adaptive response is basically when the body stores a memory of any previous invading pathogens, in order to help fight it off again in the future. The cells required for these processes are regulated and activated during sleep.

The body follows a natural internally regulated sleep and wake cycle, known as the circadian rhythm, and theres evidence to support that many cells in the immune system also follow this rhythm, with certain cells peaking during nocturnal sleep, Rollinson adds.

She adds that our bodies also burn lots of energy when combatting or recovering from illness, so sleep is really important in helping to fight off any bugs you encounter throughout the day.

3. Not eating a healthy balanced diet:

Everything we eat and drink has an effect on our body, and while its fine to treat yourself every now and then, regularly gorging on junk food does little to help our immune system, advises Dr Joshua Berkowitz, medical director at IV Boost (ivboost.uk).

Berkowitz says we should be eating nutritious food with lots of fresh seasonal fruit and vegetables.

Prioritise a balanced diet full of whole foods, with five to seven portions of vegetable and fruit per day, adds Rollinson, and factor in a good balance of good protein, quality carbohydrates and some healthy fats from good sources too.

Berkowitz also says: I recommend reducing sugar intake, as this increases inflammation in the body, which can slow down the immune system.

Emily Rollason, senior nutritionist at Holland & Barrett

4. Being deficient in vitamin D:

Vitamin D, also know as the sunshine vitamin, is an essential nutrient for healthy immune functioning, yet many of us are unknowingly running low.

Despite its name, vitamin D acts more like a hormone in the body, rather than a vitamin, says nutritionist Isabel Tarrant.

It works to activate key immune cells, known as T cells, which play a crucial role in fighting infections. The vitamin also supports immune functioning by regulating anti-microbial compounds and helping clear harmful bacteria from immune cells.

As most of our vitamin D comes from sunlight, government guidelines suggest people in the UK take a daily supplement during autumn and winter months, when there isnt enough sun to meet our needs.

Dr Joshua Berkowitz, of IV Boost UK

5. Poor gut health:

The gut is a very important part of the immune system, and theres increasing evidence to suggest we shouldnt overlook the power of our gut microbiome.

We have approximately 100 trillion live bacteria living inside of us, equating to 2kg of our body weight, says Tarrant. This friendly bacteria is essential for our health, and is involved in the smooth functioning of lots of different bodily processes, from the digestive and immune systems to your mood, brain health and skin.

Tarrant explains that gut bacteria produce metabolites, such as short chain fatty acids, which play a crucial role in regulating our T-cells, the key peace-keeper cells of our immune system. Gut bacteria also produce compounds which support the healthy functioning of white blood cells, known as macrophages, Tarrant adds, which are key for fighting off infections and harmful germs.

With stress and anxiety at a high at the moment, its easy for your gut health to suffer. Poor diet, high sugar and alcohol intake, excessive antibiotic usage, poor sleep and stress can all contribute to an imbalance in gut bacteria and an increase in negative bacteria, known as dysbiosis.

The good news is theres lots you can do to help improve your gut microbiome too and variety is key here. Try eating a more fibrous diet, advises Tarrant. Go for colourful plant foods to ensure you are consuming a diverse range of fibres, such as carrots, yellow peppers, berries, aubergine, spinach, red cabbage, beetroot, broccoli, legumes, nuts and seeds.

Prebiotics are another great way to promote a healthy gut too. These are live friendly bacteria, which can be found in foods such as sauerkraut, live yogurt, kombucha, kefir and tempeh. Alternatively, there are a range of probiotic supplements on the market to promote a healthy gut.

Consider your sleep and stress levels too. Emerging evidence shows a powerful bi-directional relationship between the gut and the brain, known as the gut-brain axis, and stress can cause havoc to the balance of positive and negative bacteria in your gut, says Tarrant.

Try to manage your stress levels by gentle walks in nature, meditation, yoga or talking to a friend. Promoting a healthy gut is all about lifestyle and wellbeing as a whole, which are key to supporting a healthy immune system this winter.

View original post here:
Five ways you might be secretly sabotaging your immune system - The Irish News

Andrew Ellsworth, MD, Prairie Doc Published 9:28 p.m. CT Oct. 29, 2020

Andrew Ellsworth, MD(Photo: Submitted)

Indeed, there is a lot we can worry about in the world today. It can be so easy to let those problems invade our thoughts as we try to get some sleep.Ideally, our bedrooms are sanctuaries of peace and quiet and places of rest. But televisions, phones, computers, and other devices bring the world and its problems to our beds, and this is not healthy.

Sleep is one of the best ways to help keep our immune system strong to fight off infection and illnesses. And now more than ever, it is important to give our bodies the best chance at fighting off a cold, flu, and disease.Adults need seven to eight hours of sleep every night, while teenagers and elementary children need nine to ten hours.

Regular exercise is one way to help us sleep better. It is best to exercise during the day rather than right before bedtime. We sleep better if we avoid eating large meals within two to three hours of going to bed. But this doesnt mean we must go to bed hungry. We can reach for a small healthy snack like carrot sticks or apple slices.It can also help to keep a regular schedule and have a bedtime ritual, such as brushing our teeth after that final snack.

Reduce caffeine and alcohol consumption, especially near bedtime.And when stressed, we can prepare for better sleep if we take time to relax by gentle stretching, meditation, prayer, or deep breathing.

We can help ourselves by changing our behaviors, but if we experience persistent heartburn or reflux, restless legs, snoring, daytime fatigue, or use the bathroom frequently at night, its time to visit the doctor for assistance.

Finally, it helps to keep the bedroom comfortable, quiet, dark, and cool.Despite all their conveniences, consider removing those electronic devices from the bedroom. Screen time before bed, whether watching television, phones or laptops is a large and growing reason for insomnia. The bright light from screens tricks our minds into thinking it is daytime so be sure to use the night filter to decrease the amount of light they emit. And, since our bedroom is meant for sleeping, why not set a firm time to turn off all the devices for the day.

You better get up; people die in their sleep. Thats what my dad would say when he was trying to get me out of bed as a teenager. While true, the reverse is also valid, people can die from problems stemming from lack of sleep. So, lets get some sleep and stay healthy out there people!

Andrew Ellsworth, M.D. is part of The Prairie Doc team of physicians and currently practices family medicine in Brookings. Prairie Doc is broadcast on SDPB most Thursdays at 7 p.m. CT.

Read or Share this story: https://www.argusleader.com/story/news/brandon/2020/10/29/sleep-one-best-ways-keep-immune-system-strong/6080249002/

Read this article:
Sleep is one of the best ways to keep immune system strong - Argus Leader

SEATTLE, Oct. 28, 2020 /PRNewswire/ --A COVID-19 immune response study has revealed new findings that suggest that treatments aimed at arresting the infection at the stage of moderate severity may be most effective. The symptoms of COVID-19 vary widely, from very mild to severe conditions requiring ICU care. Researchers comprehensively studied a large number of patients during the week following a COVID-19 diagnosis, and found that mild COVID-19 is very distinct from the moderate or severe forms of disease, which appear surprisingly similar.

For both moderate and severe COVID-19 cases, the team found that there is a sort of tug-of-war taking place, in which inflammation is promoting a stronger immune response, yet many of the key nutrients required for building that response are depleted. This leads to unusual and dysfunctional immune responses.

A paper describing these findings has been accepted by Cell, and appeared online today. The study was led by the Institute for Systems Biology (ISB) and Swedish in Seattle, with help from Merck (known as MSD outside the United States and Canada), BARDA, and several other institutions and companies (listed below).

"These findings have practical implications for treatment of patients with COVID-19. Since patients with moderate illness have not yet developed end organ damage, our data suggest that early in the disease course would be the best time to intervene with various treatment options to prevent the immune, protein and metabolite derangements seen with more severe disease," said Dr. Jason Goldman of Swedish, who is the clinical lead for the study. "Our translational data align with data from randomized control trials, which have shown greater benefits from antiviral therapies given early. These data also provide intriguing hypotheses about the targeting of host-directed therapies, or even nutritional supplementation."

The research team examined serial blood draws from 139 COVID-19 patients of all severities, from patients recovering at home to critically ill patients and in the ICU. From each blood sample, they measured thousands of proteins and metabolites to capture the environment of the circulating immune system. They also measured thousands of genes and proteins from individual immune cells. Finally, they utilized novel computational methods to merge all of these observations together to provide an integrated view of COVID-19 infection during the week following initial diagnosis.

"This is what we mean by 'systems biology' -- thoroughly measure every component of the whole system, and then use computational methods to reassemble it back together again," said ISB President Dr. Jim Heath, who was the scientific lead of the study.

"The resources provided from this work could provide high value in developing new therapies that might target metabolite starvation, immune dysfunction, or blood clotting, each of which we see emerge at the level of moderate disease," said Dr. Yapeng Su, an ISB research scientist and lead author on the study.

"This important and comprehensive study, in which Merck has been proud to participate, demonstrates the power of an integrated systems biology approach to dissect the complexity of molecular and cellular responses in patients suffering from COVID-19," said Dr. Roger M. Perlmutter, President, Merck Research Laboratories. "As we had hoped, the analysis defines a possible point of intervention in the progression of COVID-19 disease, which may in the near term permit the development of more effective, targeted therapeutics."

The COVID-19 Immune Response Study is made up by ISB, Swedish, Merck, Stanford University, Fred Hutchinson Cancer Research Center, Adaptive Biotechnologies, Bloodworks Northwest, Gilead, Isoplexis, Metabolon, Nanostring, Olink, Providence Molecular Genomics Laboratory, Scisco Genetics and 10x Genomics.

Funding for this project comes from Merck and the Biomedical Advanced Research and Development Authority (BARDA), the Wilke Family Foundation, the MJ Murdock Charitable Trust, the Swedish Medical Center Foundation, the Parker Institute for Cancer Immunotherapy, Gilead, Novartis, Amazon Web Services, Omeros, the Washington State Andy Hill CARE Fund, the Department of Defense, and the National Institutes of Health.

About ISB Institute for Systems Biology (ISB) is a collaborative and cross-disciplinary non-profit biomedical research organization based in Seattle. We focus on some of the most pressing issues in human health, including brain health, cancer, sepsis and aging, as well as many chronic and infectious diseases. Our science is translational, and we champion sound scientific research that results in real-world clinical impacts. ISB is an affiliate of Providence, one of the largest not-for-profit health care systems in the United States. Follow us online at http://www.isbscience.org, and on Facebookand Twitter.

About Swedish Founded in 1910, Swedish, affiliated with the Providence health system, is the largest nonprofit health provider in the Greater Seattle area. Swedish is comprised of five hospital campuses (First Hill, Cherry Hill, Ballard, Edmonds and Issaquah); ambulatory care centers in Redmond and Mill Creek; and a network of more than 115 primary care and specialty-care clinics located throughout the Greater Puget Sound area. Swedish is known as a regional referral center, providing specialized treatment in areas such as cardiovascular care, cancer care, neuroscience, orthopedics, high-risk obstetrics, pediatric specialties, organ transplantation and clinical research. In 2019, Swedish provided $228 million in community benefit programs, including $22 million in free and discounted care in Western Washington.

Contact: Joe Myxter 206.732.2157

SOURCE Institute for Systems Biology

Continued here:
COVID-19 Immune Response Study Could Lead to More Effective Treatments - PRNewswire

New study finds coronaviruses are masters of mimicry, reproducing their host's immune proteins to remain invisible and help promote infection.

Colorized scanning electron micrograph of a VERO E6 cell (blue) heavily infected with SARS-COV-2 virus particles (orange). Image credit: NIAID

Imitation is the sincerest form of flattery, and in nature, it also serves a practical purpose. Many plants and animals use mimicry to trick both prey and predators, but it takes on a deadly form when viruses employ similar strategies.

Viruses have adapted an arsenal of elegant and ever-changing strategies to evade detection by the immune system, one of which is to produce mimics of human immune proteins, such as cytokines, chemokines, and their receptors, that play a vital role in the bodys immune response. This allows them to promote infection and remain unseen and therefore unchecked by the hosts body.

Mimicry is a more pervasive strategy among viruses than we ever imagined, said Sagi Shapira assistant professor of systems biology at Columbia University Vagelos College of Physicians and Surgeons. Its used by all kinds of viruses, regardless of the size of the viral genome, how the virus replicates, or whether the virus infects bacteria, plants, insects, or people.

Shapira is part of a team of scientists who published a new study in the journal Cell Systems, which demonstrates that coronaviruses like SARS-CoV-2 are adept at this, imitating human immune proteins that have implications in severe cases of COVID-19.

Using powerful computers and a program similar to 3D facial recognition software to match viral proteins with their immune protein mimics, the team scanned more than 7,000 viruses and over 4,000 hosts and uncovered 6 million instances of viral mimicry.

While this underscored the phenomenons prevalence, the team was surprised to find that some families of viruses, such as Papilloma and retroviruses, use it less than others. The coronavirus family on the other hand was found to exhibit a high level of diversification and structural promiscuity in the human proteins they mimic, with over 150 protein examples identified in the current study.

Interestingly, these include many proteins that control blood coagulation or activate plasma proteins called complements, which help target pathogens for destruction and increase inflammation in the body.

We thought that by mimicking the bodys immune complement and coagulation proteins, coronaviruses may drive these systems into a hyperactive state and cause the pathology we see in infected patients, said Shapira.

In a separate paper published in Nature Medicine, the Columbia researchers found evidence that functional and genetic dysregulation in immune complement and coagulation proteins are associated with severe COVID-19 disease. They found that people with macular degeneration (which is associated with enhanced complement activation) were more likely to die from COVID-19, that complement and coagulation genes are more active in COVID-19 patients, and that people with certain mutations in complement and coagulation genes are more likely to be hospitalized for COVID-19.

Since that paper first appeared this spring in a preprint, other researchers have also found links between complement and COVID severity and several clinical trials of complement inhibitors have been initiated. Shapira says the investigation of viral protein functions and mimicry suggests that learning about underlying virus biology could be one way to gain insights into how viruses cause disease and who may be at greatest risk.

Viruses have already figured out how to exploit their hosts, Shapira says. By studying viruses we can not only reveal fundamental principles in biology but also how they perturb cellular homeostasis and cause pathology. The hope is that one day we may be able to use this knowledge to fight back.

Beyond COVID-19, the information were gathering about how individual viral proteins workacross all viruses on Earthmay one day be leveraged as building blocks in medical and agricultural interventions.

Reference: Gorka Lasso, et al. A Sweep of Earths Virome Reveals Host-Guided Viral Protein Structural Mimicry and Points to Determinants of Human Disease, Cell Systems (2020). DOI: 10.1016/j.cels.2020.09.006

Adapted from press release provided by Columbia University Irving Medical Center

Original post:
Coronaviruses mimic immune proteins and hide in plain sight - Advanced Science News

Read: The pandemic is in uncharted territory

Jelic was among the doctors treating COVID-19 patients in New York in the spring, when hundreds of people were turning up at the citys hospitals everyday unable to breathe. Patients were crammed into hallways; doctors were overworked. Normally, Jelic says, she might have seen eight or 10 patients in a day. In April, she and two fellows were responsible for 60, any of whom might crash and need to be intubated.

Lack of knowledge about the virus constrained what doctors did. Hospitals initially favored ventilation in part because doctors feared that high-flow therapy oxygen could aerosolize the virus and spread it to staff who didnt have adequate supplies of personal protective equipment. (Now, of course, we know that the virus can be spread through aerosols generated from just normal talking and exhaling.) In some cases, aggressive intubation might have done more harm than good in patients who didnt need it. Doctors stopped putting every patient on a ventilator once they realized the benefits of less invasive oxygen therapy and even turning patients onto their bellies, also known as proning.

Because COVID-19 can, like many conditions, manifest so differently from person to person, knowing which patients might benefitor be hurtby a treatment is a key part of the learning curve. There isnt a one-size-fits-all treatment, says Nicholas Caputo, a doctor at Lincoln Hospital in the Bronx, who was one early advocate of proning. Ventilation is one example of a treatment that can help or hurt depending on the patient. Another is dexamethasone, a steroid that suppresses the immune system. The drug has been shown to reduce mortality in patients with severe COVID-19, whose immune systems have become hyperactive, but might harm patients with milder cases whose immune systems are still trying to clear the virus.

Read: Immunology is where intuition goes to die

Doctors have also learned to watch out for COVID-19s more unusual symptoms. The disease has been linked to kidney failure; those patients might need dialysis. Its also linked to blood clots; patients who show warning signs might need blood thinners. Seeing more cases of COVID-19 has also allowed doctors to refine details like the size of tubing used with ECMO, an artificial-lung technology for the sickest patients who arent doing well on ventilators.

A lot of this experience has been shared in real time and informally. J. Eduardo Rame, a cardiologist at Thomas Jefferson University Hospitals, helps convene a regular Zoom forum where doctors discuss the latest, such as how to use ECMO. Experiential learning, as Rame puts it, has been vital for sharing information about a new disease. But doctors are also trained to rely on data and randomized, controlled trials, not anecdotes. Were nowhere near the inflection point where we can have medical care dictated by evidence, Rame says, which puts doctors in a strange position. For now, they have experience to go on, which is better than nothing. But its not data.

See more here:
The Simple Rule That Could Keep COVID-19 Deaths Down - The Atlantic